Aslan Pharmaceuticals Ltd.
(NASDAQ : ASLN)

( )
ASLN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.01%296.831.4%$601.48m
AMGNAmgen, Inc.
0.32%236.741.3%$495.31m
GILDGilead Sciences, Inc.
-2.75%65.771.0%$370.34m
REGNRegeneron Pharmaceuticals, Inc.
1.15%376.422.6%$305.23m
VRTXVertex Pharmaceuticals, Inc.
-0.71%218.981.9%$275.99m
ILMNIllumina, Inc.
0.85%324.723.5%$241.12m
CLVSClovis Oncology, Inc.
-4.24%12.8614.7%$219.13m
SRPTSarepta Therapeutics, Inc.
31.43%132.0514.6%$207.70m
ALXNAlexion Pharmaceuticals, Inc.
-1.82%110.422.0%$199.61m
ARWRArrowhead Pharmaceuticals, Inc.
-1.28%66.4611.4%$199.52m
AAgilent Technologies, Inc.
-1.30%83.711.6%$164.84m
EXASEXACT Sciences Corp.
2.08%87.2024.0%$164.17m
BLUEbluebird bio, Inc.
6.78%89.7514.2%$152.73m
GBTGlobal Blood Therapeutics, Inc.
-0.01%76.886.0%$140.08m
BOLDAudentes Therapeutics, Inc.
0.05%59.401.4%$136.27m

Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.